These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 4577966)

  • 1. Antitumor activity of anaerobic Corynebacterium isolated from the human bone marrow.
    Hattori T; Mori A
    Gan; 1973 Feb; 64(1):15-27. PubMed ID: 4577966
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacteriological survey of anaerobic Corynebacterium in human bone marrow and blood.
    Hattori T; Mori A
    Gan; 1973 Feb; 64(1):7-14. PubMed ID: 4577967
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of a single and repeated administration of Corynebacterium parvum on bone marrow macrophage colony production in syngeneic tumor-bearing mice.
    Wolmark N; Fisher B
    Cancer Res; 1974 Nov; 34(11):2869-72. PubMed ID: 4419513
    [No Abstract]   [Full Text] [Related]  

  • 4. Transient graft-versus-host reaction in the treatment of leukemia in mice.
    Boranić M
    J Natl Cancer Inst; 1968 Aug; 41(2):421-37. PubMed ID: 4876445
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunogenicity and pathogenicity factors of Corynebacterium pyogenes. 1. Trials of immunity development against Corynebacterium pyogenes infections in the mouse model].
    Durner K; Werner B
    Arch Exp Veterinarmed; 1983 Jul; 37(4):541-7. PubMed ID: 6360071
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of BCG and Corynebacterium Parvum on allograft survival after rabbit antimouse lymphocyte serum and donor bone marrow.
    Clark AW; Monaco AP
    Surg Forum; 1973; 24():340-3. PubMed ID: 4618660
    [No Abstract]   [Full Text] [Related]  

  • 7. Restoration of prostaglandin E2-producing splenic macrophages in 89Sr-treated mice with bone marrow from Corynebacterium parvum primed donors.
    Shibata Y
    Reg Immunol; 1989; 2(3):169-75. PubMed ID: 2641504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active enhancement of tissue allografts with antilymphocyte serum and bone marrow.
    Monaco AP; Liegeois A; Wood ML; Clark AW
    Adv Nephrol Necker Hosp; 1975; 5():135-72. PubMed ID: 242206
    [No Abstract]   [Full Text] [Related]  

  • 9. Antitumour effect of different corynebacterial immunostimulants in non isogenic mouse-tumour-system. (Short communication).
    Géresi M; Réthy L; Ecsy R; Gelencsér F; Padányi M; Pogány I; Bácskai L; Réthy LA
    Acta Vet Acad Sci Hung; 1981; 28(3):281-3. PubMed ID: 7258017
    [No Abstract]   [Full Text] [Related]  

  • 10. [Use of bone marrow transplantation in the treatment of gastric cancer and its evaluation with special reference to anerobic Corynebacterium].
    Hattori T; Yagi H; Murakami H; Ushijima K; Mori A
    Gan No Rinsho; 1969 Jan; 15(1):39-47. PubMed ID: 4888575
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro modification of donor bone marrow used to produce enhanced graft survival in antilymphocyte serum (ALS)-treated mice.
    Gozzo JJ; Wood ML; Pompei R; Monaco AP
    Transplant Proc; 1973 Mar; 5(1):853-6. PubMed ID: 4572148
    [No Abstract]   [Full Text] [Related]  

  • 12. Influence of Ehrlich ascites carcinoma on repopulating ability of mouse bone marrow cells.
    Clerici E; Mocarelli P; Villa ML; Natale N
    J Natl Cancer Inst; 1971 Sep; 47(3):555-60. PubMed ID: 4945589
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of antilymphocyte sera on bone marrow allograft rejection.
    Riches AC; Thomas DB
    Exp Hematol; 1975 Jun; 3(3):169-80. PubMed ID: 1098919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments.
    Wood ML; Gozzo JJ; Monaco AP
    Transplant Proc; 1972 Dec; 4(4):523-9. PubMed ID: 4405146
    [No Abstract]   [Full Text] [Related]  

  • 15. Studies on the biological and serological properties of Corynebacterium pyogenes.
    Tainaka M; Kume T; Takeuchi S; Nishio S; Saito H
    Kitasato Arch Exp Med; 1983 Dec; 56(4):105-17. PubMed ID: 6392695
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of bone marrow aplasia by bone marrow graft after conditioning with antilymphocyte globulin. Long term results.
    Mathé G; Schwarzenberg L
    Exp Hematol; 1976 Jul; 4(4):256-64. PubMed ID: 782897
    [No Abstract]   [Full Text] [Related]  

  • 17. Bone marrow transplantation in children.
    Dooren LJ; Kamphuis RP; de Koning J; Vossen JM
    Semin Hematol; 1974 Jul; 11(3):369-82. PubMed ID: 4599790
    [No Abstract]   [Full Text] [Related]  

  • 18. Allograft enhancement induced by bone marrow cells.
    Liegeois A; Charreire J; Brennan LB
    Surg Forum; 1974; 25(0):297-300. PubMed ID: 4612783
    [No Abstract]   [Full Text] [Related]  

  • 19. Cell-mediated immunity and serum blocking factor in tolerance produced in mice with antilymphocyte serum and bone marrow cell infusion.
    Wood ML; Gozzo JJ; Heppner G; Monaco AP
    Transplant Proc; 1972 Sep; 4(3):383-9. PubMed ID: 4263511
    [No Abstract]   [Full Text] [Related]  

  • 20. Haemagglutinating ability of Corynebacterium pyogenes strains isolated from domestic animals.
    Forray A
    Acta Vet Acad Sci Hung; 1971; 21(2):261-5. PubMed ID: 4946252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.